New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...

Findings demonstrate ATYR2810's anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

A new, small cancer study may give hope to patients with solid tumors in the stomach, esophagus or rectum. The standard ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...